全文获取类型
收费全文 | 293722篇 |
免费 | 59674篇 |
国内免费 | 786篇 |
专业分类
耳鼻咽喉 | 3836篇 |
儿科学 | 10011篇 |
妇产科学 | 5099篇 |
基础医学 | 43939篇 |
口腔科学 | 9703篇 |
临床医学 | 33302篇 |
内科学 | 69402篇 |
皮肤病学 | 10225篇 |
神经病学 | 34049篇 |
特种医学 | 9607篇 |
外国民族医学 | 13篇 |
外科学 | 48404篇 |
综合类 | 3670篇 |
现状与发展 | 2篇 |
一般理论 | 330篇 |
预防医学 | 24273篇 |
眼科学 | 5937篇 |
药学 | 20692篇 |
2篇 | |
中国医学 | 1382篇 |
肿瘤学 | 20304篇 |
出版年
2023年 | 831篇 |
2022年 | 1502篇 |
2021年 | 4883篇 |
2020年 | 7101篇 |
2019年 | 14062篇 |
2018年 | 14037篇 |
2017年 | 14529篇 |
2016年 | 15350篇 |
2015年 | 15880篇 |
2014年 | 17898篇 |
2013年 | 21270篇 |
2012年 | 17976篇 |
2011年 | 19026篇 |
2010年 | 17221篇 |
2009年 | 12814篇 |
2008年 | 16316篇 |
2007年 | 16054篇 |
2006年 | 15613篇 |
2005年 | 15840篇 |
2004年 | 15231篇 |
2003年 | 14290篇 |
2002年 | 13888篇 |
2001年 | 2770篇 |
2000年 | 2287篇 |
1999年 | 2460篇 |
1998年 | 3021篇 |
1997年 | 2618篇 |
1996年 | 2363篇 |
1995年 | 2081篇 |
1994年 | 1887篇 |
1993年 | 1791篇 |
1992年 | 1325篇 |
1991年 | 1293篇 |
1990年 | 1149篇 |
1989年 | 1061篇 |
1988年 | 1120篇 |
1987年 | 1116篇 |
1986年 | 1102篇 |
1985年 | 1170篇 |
1984年 | 1570篇 |
1983年 | 1564篇 |
1982年 | 1912篇 |
1981年 | 1741篇 |
1980年 | 1642篇 |
1979年 | 920篇 |
1978年 | 1040篇 |
1977年 | 1000篇 |
1976年 | 888篇 |
1975年 | 758篇 |
1974年 | 722篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
102.
103.
104.
105.
Tuberculosis (TB) remains one of a major health problem worldwide. Tuberculosis vaccine research has made an extraordinary progress over the past few years. However, there is still no replacement for the Bacillus Calmette‐Guérin vaccine, the only TB vaccine licensed for human use. Therefore, the discovery and development of new TB vaccines remains a priority. This article discusses current strategies used to diversify TB vaccines and includes discussion of the status of efforts to improve protection against Mycobacterium tuberculosis (M tb) infection or TB disease by developing new and safe TB vaccines. This article also highlights the current research efforts in immune‐enhancing approaches to improve vaccination efficacy. The development of more effective TB vaccines might have significant impact on global TB control. 相似文献
106.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
107.
Michael W. Manning Yi-Ju Li Dean Linder John C. Haney Yi-Hung Wu Mihai V. Podgoreanu Madhav Swaminathan Jacob N. Schroder Carmelo A. Milano Ian J. Welsby Mark Stafford-Smith Kamrouz Ghadimi 《Journal of cardiothoracic and vascular anesthesia》2021,35(5):1310-1318
- Download : Download high-res image (215KB)
- Download : Download full-size image
108.
Shylo R. Johnson Dennis Slate Kathleen M. Nelson Amy J. Davis Samual A. Mills John T. Forbes Kurt C. VerCauteren Amy T. Gilbert Richard B. Chipman 《Viruses》2021,13(2)
Since the 1990s, oral rabies vaccination (ORV) has been used successfully to halt the westward spread of the raccoon rabies virus (RV) variant from the eastern continental USA. Elimination of raccoon RV from the eastern USA has proven challenging across targeted raccoon (Procyon lotor) and striped skunk (Mephitis mephitis) populations impacted by raccoon RV. Field trial evaluations of the Ontario Rabies Vaccine Bait (ONRAB) were initiated to expand ORV products available to meet the rabies management goal of raccoon RV elimination. This study describes the continuation of a 2011 trial in West Virginia. Our objective was to evaluate raccoon and skunk response to ORV occurring in West Virginia for an additional two years (2012–2013) at 75 baits/km2 followed by three years (2014–2016) of evaluation at 300 baits/km2. We measured the change in rabies virus-neutralizing antibody (RVNA) seroprevalence in targeted wildlife populations by comparing levels pre- and post-ORV during each year of study. The increase in bait density from 75/km2 to 300/km2 corresponded to an increase in average post-ORV seroprevalence for raccoon and skunk populations. Raccoon population RVNA levels increased from 53% (300/565, 95% CI: 50–57%) to 82.0% (596/727, 95% CI: 79–85%) during this study, and skunk population RVNA levels increased from 11% (8/72, 95% CI: 6–20%) to 39% (51/130, 95% CI: 31–48%). The RVNA seroprevalence pre-ORV demonstrated an increasing trend across study years for both bait densities and species, indicating that multiple years of ORV may be necessary to achieve and maintain RVNA seroprevalence in target wildlife populations for the control and elimination of raccoon RV in the eastern USA. 相似文献
109.
Clint R. Bellenger John B. Arnold Jonathan D. Buckley Dominic Thewlis Joel T. Fuller 《Journal of Science and Medicine in Sport》2019,22(3):294-299
Objectives
To investigate whether functional overreaching affects locomotor system behaviour when running at fixed relative intensities and if any effects were associated with changes in running performance.Design
Prospective intervention study.Methods
Ten trained male runners completed three training blocks in a fixed order. Training consisted of one week of light training (baseline), two weeks of heavy training designed to induce functional overreaching, and ten days of light taper training designed to allow athletes to recover from, and adapt to, the heavy training. Locomotor behaviour, 5-km time trial performance, and subjective reports of training status (Daily Analysis of Life Demands for Athletes (DALDA) questionnaire) were assessed at the completion of each training block. Locomotor behaviour was assessed using detrended fluctuation analysis of stride intervals during running at speeds corresponding to 65% and 85% of maximum heart rate (HRmax) at baseline.Results
Time trial performance (effect size ±95% confidence interval (ES): 0.16 ± 0.06; p < 0.001), locomotor behaviour at 65% HRmax (ES: ?1.12 ± 0.95; p = 0.026), and DALDA (ES: 2.55 ± 0.80; p < 0.001) were all detrimentally affected by the heavy training. Time trial performance improved relative to baseline after the taper (ES: ?0.16 ± 0.10; p = 0.003) but locomotor behaviour at 65% HRmax (ES: ?1.18 ± 1.17; p = 0.048) and DALDA (ES: 0.92 ± 0.90; p = 0.045) remained impaired.Conclusions
Locomotor behaviour during running at 65% HRmax was impaired by functional overreaching and remained impaired after a 10-day taper, despite improved running performance. Locomotor changes may increase injury risk and should be considered within athlete monitoring programs independently of performance changes. 相似文献110.